76918-64-4

Usage

Uses

Used in Pharmaceutical Synthesis:
ETHYL 4-AMINO-3-NITROBENZOATE is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the formation of complex molecular structures that can exhibit therapeutic properties.
Used in Dye Production:
In the dye industry, ETHYL 4-AMINO-3-NITROBENZOATE is used as a chemical intermediate to produce a range of dyes, capitalizing on its capacity to form colorants with specific characteristics.
Used in Organic Chemistry Research:
ETHYL 4-AMINO-3-NITROBENZOATE serves as a valuable compound in organic chemistry research, where it is employed to study reaction mechanisms, explore new synthetic pathways, and develop novel chemical methodologies.
Used in Medicinal Chemistry:
ETHYL 4-AMINO-3-NITROBENZOATE is being studied for its potential biological activities, with the aim of identifying its possible use in the development of new drugs and therapeutic agents in medicinal chemistry.

InChI:InChI=1/C9H10N2O4/c1-2-15-9(12)6-3-4-7(10)8(5-6)11(13)14/h3-5H,2,10H2,1H3

Upstream product

• 1539-06-6 3-nitro-4-acetamidobenzoic acid 
• 64-17-5 ethanol 
• 1588-83-6 4-amino-3-nitrobenzoic acid 
• 175204-17-8 ethyl 4-(acetylamino)-3-nitrobenzoate 
• 959928-89-3 ethyl 4-(pyrimidin-2-ylamino)benzoate 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 367-80-6 ethyl 4-fluoro-3-nitrobenzoate 
• 937625-32-6 ethyl 4-ethoxy-3-nitrobenzoate 
• 7664-41-7 ammonia 
• 168473-87-8 ethyl 4-bromo-3-nitrobenzoate 

Downstream Products

• 37466-90-3 ethyl 3,4-diaminobenzoate 
• 41263-65-4 4-amino-3-nitrobenzamide 
• 175204-17-8 ethyl 4-(acetylamino)-3-nitrobenzoate 
• 861604-86-6 4-(2-chloro-acetylamino)-3-nitro-benzoic acid ethyl ester 
• 93415-80-6 N-(4'-Carboethoxy-2'-nitrophenyl)-5-amino-6-nitro-1,3-benzdioxol 
• 71005-26-0 4-azido-3-nitro-benzoic acid ethyl ester 
• 199535-31-4 4-[(Furan-2-carbonyl)-amino]-3-nitro-benzoic acid ethyl ester 
• 543740-76-7 4-amino-3-iodo-5-nitrobenzoic acid ethyl ester 
• 840531-23-9 ethyl 4-[(3-cyanobenzoyl)amino]-3-nitrobenzoate 
• 645409-72-9 ethyl 4-{[(E)-(dimethylamino)methylidene]amino}-3-iodo-5-nitrobenzoate 
• 89677-77-0 4-amino-3-iodo-5-nitrobenzoic acid 
• 199535-32-5 3-Amino-4-[(furan-2-carbonyl)-amino]-benzoic acid ethyl ester 
• 142015-36-9 ethyl 3-nitro-4-valerylaminobenzoate 

Relevant academic research and scientific papers

Synthesis and Crystal Structures of Ethyl 2-(4-Methoxyphenyl)-1H-benzo[d]imidazole-5-carboxylate Dihydrate and Its Building Block 4-Fluoro-3-nitrobenzoic Acid

The title compound, ethyl 2-(4-methoxyphenyl)-1H-benzo[d]imidazole-5-carboxylate dihydrate (5), was synthesized and its crystal structure was studied by single-crystal X-ray diffraction technique. Compound 5 is crystallized in the centrosymmetric triclinic space group P1 ˉ with Z = 4 and Z′ = 2, and unit-cell parameters of a = 8.9190 (3) ?, b = 12.6888 (4) ?, c = 14.7111 (5) ?, α = 98.4855 (10)°, β = 101.6379 (9)°, γ = 95.4346 (10)° and V = 1599.43 (9) ?3. Its starting material, 4-fluoro-3-nitrobenzoic acid (1), is crystallized in the non-centrosymmetric monoclinic space group P21 and Z = 4 with unit-cell parameters of a = 3.7170 (4) ?, b = 12.6475 (13) ?, c = 15.5237 (15) ?, α = 90°, β = 91.9786 (16)°, γ = 90° and V = 729.35 (13) ?3. It was noted that strong hydrogen bonds play important roles in the crystal packing of both compounds, especially in 5, in which the co-crystallized water molecules act as both strong hydrogen bond donor and strong hydrogen bond acceptor. Graphical Abstract: Two molecule of compound 5 crystallized in a non symmetrical manner with four co-crystallized water molecules which play an important role in the crystal packing as strong hydrogen-bond donors. [Figure not available: see fulltext.].

ANTI-ANGIOGENIC AGENTS AND USES THEREOF

There is herein disclosed a compound of formula I: or a salt solvate or pharmaceutically acceptable derivative thereof, wherein R1 to R7 is as defined herein for use in the treatment of angenogenis and related conditions.

COMPOUND AND METHOD FOR INHIBITING SIRTUIN ACTIVITIES

A compound of formula wherein R1 is selected from the group consisting of hydrogen, halogen, hydroxyl, carboxyl, alkyl of up to 5 carbon atoms, imidazolyl, piperazinyl, morpholinyl, benzyl, R4OH or R4COOH, where R4 is (CH2)m and m is an integer of from 1 to 4; R2 is selected from the group consisting of hydrogen, phenyl or 3-(2-oxopyrrolidin-l-yl) propyl; and R3 is hydrogen or alkyl of from 1-4 carbon atoms.

As cell necrosis inhibitors of the indole compounds (by machine translation)

The invention relates to chemical formula (1) indole compounds, or its pharmaceutically acceptable salt or isomer, and in containing the same as the characteristic, as an active ingredient for the prevention or treatment of cell necrosis and its associated disease composition and method of manufacturing. (by machine translation)

INDOLE COMPOUND AS INHIBITOR OF NECROSIS

The present invention relates to an indole compound represented by formula (1), a pharmaceutically acceptable salt or isomer thereof, a composition for prevention or treatment of necrosis and necrosis-associated diseases, and a method for preparing the composition, the composition comprising the indole compound or the pharmaceutically acceptable salt or isomer thereof as an active ingredient.

Palladium(II)-catalyzed, heteroatom-directed, regioselective C-H nitration of anilines using pyrimidine as a removable directing group

A new palladium-catalyzed, heteroatom-directed strategy for C-H nitration of anilines is described. This C-H functionalization reaction is highly ortho-selective and results in very good yields. The highlight of the work is the use of pyrimidine as the removable directing group. This approach constitutes one of the rare methods of ortho-nitration of anilines, a reaction that is normally very difficult to achieve via traditional approaches.

Synthesis and evaluation of antimycobacterial activity of new benzimidazole aminoesters

Abstract A total of 51 novel benzimidazoles were synthesized by a 4-step reaction starting from basic compound 4-fluoro-3-nitrobenzoic acid under relatively mild reaction conditions. The structure of the novel benzimidazoles was confirmed by mass spectra as well as 1H NMR spectroscopic data. Out of the 51 novel synthesized compounds, 42 of them were screened for their antimycobacterial activity against Mycobacterium tuberculosis H37Rv strain using BacTiter-Glo Microbial Cell Viability (BTG) method. Results of activity screened using Alamar Blue method was also provided for comparison purposes. Two of the novel benzimidazoles synthesized showed moderately good activity with IC50 of less than 15 μM. Compound 5g, ethyl 2-(4-(trifluoromethyl)phenyl)-1-(2-morpholinoethyl)-1H-benzo[d]imidazole-5-carboxylate, was found to be the most active with IC50 of 11.52 μM.

Discovery of a potent and highly fluorescent sirtuin inhibitor

In search for potent sirtuin inhibitors, a series of diversified 1,2-disubstituted benzimidazole analogues were synthesized using a one-pot method. The most potent compound in the series (BZD9L1) was discovered to show high autofluorescence which can be utilized to predict its localization in cells. More importantly, BZD9L1 displayed strong antiproliferative effects against a panel of cancer cells tested. Molecular docking studies also help to explain the observed structure-activity relationship.

Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors

Abstract The coagulation factor Xa (FXa) plays a central role in the blood coagulation cascade. Recent studies have shown that FXa is a particularly attractive target for the development of oral antithrombotic agents. In view of the excellent pharmaceutical properties of 1,2-phenylenediamine-based FXa inhibitors and the reported structureeactivity relationship (SAR) analysis of FXa inhibitors, we designed and synthesized a series of 3,4-diaminobenzoyl-based FXa inhibitors. Intensive SAR studies on this new series led to the discovery of 3,4-dimethoxyl substituted compound 7b. 7b is a highly potent, selective, direct FXa inhibitor with excellent in vivo antithrombotic activity.

Indole and indazole compounds as an inhibitor of cellular necrosis

The present invention refers to a formula (1) compounds of, pharmaceutically acceptable salts or isomers thereof thereof, and characterized by by containing as active ingredients-associated diseases, cell death and method for the prevention or treatment of relates and compositions. [Formula 1] In formula said R 1, R 2, R 3, R 4, R 5, R 6, A, X, n and m to equal the specification.